Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190030/S004

ActaStim-S

Theragen, Inc. · Decision date May 13, 2026

FDA DECISIONP190030/S004

What did the FDA approve?

FDA records P190030/S004 as a supplement to PMA P190030, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 13, 2026.

FDA approval order statement

Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Orthopedic
Decision date
May 13, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P190030/S004
Regulatory pathway
PMA supplement
Product code
LOF
Decision code
APPR
Decision date
May 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, bone growth, non-invasive.

Product code
LOF
FDA device class
2

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190030/S004 received

    Application receipt date recorded by FDA.

  2. P190030/S004 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P190030. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code LOF

Product / regulatory recordCompanyPathwayDecision dateSource
Djo, LLC510(k) clearanceSep 29, 2026FDA
Bioventus, LLCPMA supplementMar 6, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Theragen, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
11220 Assett Loop, Suite 101, Manassas, VA, 20109

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records